The potential of class 3 semaphorins as both targets and therapeutics in cancer

Bibliography

• Land H, Parada LF, Weinberg RA. Cellular oncogenes and multistep carcinogenesis. Science 1983;222:771-8
   PubMed Web of Science ®Google Scholar
• Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 1993;75:1389-99
   PubMed Web of Science ®Google Scholar
• Raper JA. Semaphorins and their receptors in vertebrates and invertebrates. Curr Opin Neurobiol 2000;10:88-94
   PubMed Web of Science ®Google Scholar
• Kolodkin AL, Matthes DJ, O’Connor TP, et al. Fasciclin IV: sequence, expression, and function during growth cone guidance in the grasshopper embryo. Neuron 1992;9:831-45
   PubMed Web of Science ®Google Scholar
• Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993;75:217-27
   PubMed Web of Science ®Google Scholar
• Yazdani U, Terman JR. The semaphorins. Genome Biol 2006;7:211
   PubMed Web of Science ®Google Scholar
• Takahashi T, Fournier A, Nakamura F, et al. Plexin-Neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999;99:59-69
   PubMed Web of Science ®Google Scholar
• He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 1997;90:739-51
   PubMed Web of Science ®Google Scholar
• Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006;5:1099-107
   PubMed Web of Science ®Google Scholar
• Gherardi E, Love CA, Esnouf RM, et al. The semadomain. Curr Opin Struct Biol 2004;14:669-78
   PubMed Web of Science ®Google Scholar
• Koppel AM, Feiner L, Kobayashi H, et al. A 70 amino acid region within the semaphorin domain activates specific cellular response of semaphorin family members. Neuron 1997;19:531-7
   PubMed Web of Science ®Google Scholar
• Koppel AM, Raper JA. Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity. J Biol Chem 1998;273:15708-13
   PubMed Web of Science ®Google Scholar
• Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71-80
   PubMed Web of Science ®Google Scholar
• Saito Y, Oinuma I, Fujimoto S, et al. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. EMBO Rep 2009;10:614-21
   PubMed Web of Science ®Google Scholar
• Wang Y, He H, Srivastava N, et al. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci Signal 2012;5:ra6
   PubMed Web of Science ®Google Scholar
• Toyofuku T, Yoshida J, Sugimoto T, et al. FARP2 triggers signals for Sema3A- mediated axonal repulsion. Nat Neurosci 2005;8:1712-19
   PubMed Web of Science ®Google Scholar
• Gu C, Yoshida Y, Livet J, et al. Semaphorin 3E and Plexin D1 control vascular pattern independently of neuropilins. Science 2005;307:265-8
   PubMed Web of Science ®Google Scholar
• Cai H, Reed RR. Cloning and characterization of Neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of Neuropilin-1. J Neurosci 1999;19:6519-27
   PubMed Web of Science ®Google Scholar
• Valdembri D, Caswell PT, Anderson KI, et al. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PloS Biol 2009;7:e25
   PubMed Web of Science ®Google Scholar
• Goel HL, Pursell B, Standley C, et al. Neuropilin-2 regulates alpha6beta1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012;125:497-506
   PubMed Web of Science ®Google Scholar
• Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics 2000;70:211-22
   PubMed Web of Science ®Google Scholar
• Gluzman-Poltorak Z, Cohen T, Herzog Y, et al. Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF) and of Placenta Growth Factor-2, but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF. J Biol Chem 2000;275:18040-5
   PubMed Web of Science ®Google Scholar
• Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45
   PubMed Web of Science ®Google Scholar
• Giger RJ, Urquhart ER, Gillespie SK, et al. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998;21:1079-92
   PubMed Web of Science ®Google Scholar
• Adams RH, Lohrum M, Klostermann A, et al. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J 1997;16:6077-86
   PubMed Web of Science ®Google Scholar
• Parker MW, Hellman LM, Xu P, et al. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 2010;49:4068-75
   PubMed Web of Science ®Google Scholar
• Gu C, Limberg BJ, Whitaker GB, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002;277:18069-76
   PubMed Web of Science ®Google Scholar
• Siebold C, Jones EY. Structural insights into semaphorins and their receptors. Semin Cell Dev Biol 2013;24:139-45
   PubMed Web of Science ®Google Scholar
• Sharma A, Verhaangen J, Harvey AR. Receptor complexes for each of the Class 3 Semaphorins. Front Cell Neurosci 2012;6:28
   PubMed Web of Science ®Google Scholar
• Cariboni A, Davidson K, Rakic S, et al. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism. Hum Mol Genet 2011;20:336-44
   PubMed Web of Science ®Google Scholar
• Banerjee S, Sengupta K, Dhar K, et al. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. Mol Carcinog 2006;45:871-80
   PubMed Web of Science ®Google Scholar
• West DC, Rees CG, Duchesne L, et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 2005;280:13457-64
   PubMed Web of Science ®Google Scholar
• Glinka Y, Stoilova S, Mohammed N, et al. Neuropilin-1 exerts co- receptor function for TGF-beta1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011;32:613-21
   PubMed Web of Science ®Google Scholar
• Hsieh SH, Ying NW, Wu MH, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 2008;27:3746-53
   PubMed Web of Science ®Google Scholar
• Hu B, Guo P, Bar-Joseph I, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/ SF autocrine pathway. Oncogene 2007;26:5577-86
   PubMed Web of Science ®Google Scholar
• Sulpice E, Plouët J, Bergé M, et al. Neuropilin-1 and neuropilin-2 act as co-receptors, potentiating pro-angiogenic activity. Blood 2008;111:2036-45
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65
   PubMed Web of Science ®Google Scholar
• Fukasawa M, Matsushita A, Korc M. Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther 2007;6:1173-80
   PubMed Web of Science ®Google Scholar
• Hochman E, Castiel A, Jacob-Hirsch J, et al. Molecular pathways regulating pro-migratory effects of Hedgehog signaling. J Biol Chem 2006;281:33860-70
   PubMed Web of Science ®Google Scholar
• Schramek H, Sarközi R, Lauterberg C, et al. Neuropilin-1 and neuropilin- 2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab Invest 2009;89:1304-16
   PubMed Web of Science ®Google Scholar
• Castellani V, Chédotal A, Schachner M, et al. Analysis of the L1-deficient mouse phenotype reveals cross-talk between SEMA3A and L1 signaling pathways in axonal guidance. Neuron 2000;27:237-49
   PubMed Web of Science ®Google Scholar
• Demyanenko GP, Riday TT, Tran TS, et al. NrCAM deletion causes topographic mistargeting of thalamocortical axons to the visual cortex and disrupts visual acuity. J Neurosci 2011;31:1545-58
   PubMed Web of Science ®Google Scholar
• Schlatter MC, Buhusi M, Wright AG, et al. CHL1 promotes Sema3A-induced growth cone collapse and neurite elaboration through a motif required for recruitment of ERM proteins to the plasma membrane. J Neurochem 2008;104:731-44
   PubMed Web of Science ®Google Scholar
• Hernández-Miranda LR, Cariboni A, Faux C, et al. Robo1 regulates semaphorin signaling to guide the migration of cortical interneurons through the ventral forebrain. J Neurosci 2011;31:6174-87
   PubMed Web of Science ®Google Scholar
• Pan H, Wanami LS, Dissanayake TR, et al. Autocrine Semaphorin3A stimulates alpha2beta1 integrin expression/function in breast tumor cells. Breast Cancer Res Treat 2009;118:197-205
   PubMed Web of Science ®Google Scholar
• Mishra R, Thorat D, Soundararajan G, et al. Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis. Oncogene 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, et al. Semaphorin-3A and Semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007;282:26294-305
   PubMed Web of Science ®Google Scholar
• Appleton BA, Wu P, Maloney J, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 2007;26:4902-12
   PubMed Web of Science ®Google Scholar
• Acevedo LM, Barillas S, Weis SM, et al. Semaphorin 3A suppresses VEGF- mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008;111:2674-80
   PubMed Web of Science ®Google Scholar
• Kigel B, Varshavsky A, Kessler O, et al. Successful inhibition of tumor development by specific Class-3 Semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 2008;3:e3287
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Kumar S, Mishra R, et al. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One 2012;7:e33633
   PubMed Web of Science ®Google Scholar
• Herman JG, Meadows GG. Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 2007;30:1231-8
   PubMed Web of Science ®Google Scholar
• Catalano A, Caprari P, Rodilossi S, et al. Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J 2004;18:358-60
   PubMed Web of Science ®Google Scholar
• Bagci T, Wu JK, Pfannl R, et al. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 2009;28:3537-50
   PubMed Web of Science ®Google Scholar
• Castro-Rivera E, Ran S, Brekken RA, et al. Semaphorin 3B inhibits the Phosphatidylinositol 3-Kinase/Akt pathway through Neuropilin-1 in lung and breast cancer cells. Cancer Res 2008;68:8295-303
   PubMed Web of Science ®Google Scholar
• Varshavsky A, Kessler O, Abramovitch S, et al. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertase. Cancer Res 2008;68:6922-31
   PubMed Web of Science ®Google Scholar
• Castro-Rivera E, Ran S, Thorpe P, et al. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 2004;101:11432-7
   PubMed Web of Science ®Google Scholar
• Nguyen H, Ivanova VS, Kavandi L, et al. Progesterone and 1, 25-Dihydroxyvitamin D3 inhibit endometrial cancer cell growth by upregulating Semaphorin 3B and Semaphorin 3F. Mol Cancer Res 2011;9:1479-92
   PubMed Web of Science ®Google Scholar
• Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, non-metastatic tumor phenotype. J Clin Invest 2004;114:1260-71
   PubMed Web of Science ®Google Scholar
• Kusy S, Nasarre P, Chan D, et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 2005;7:457-65
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Wu YN, Ye JH, et al. Effect of human semaphorin-3F gene transient transfection on the proliferation of tongue carcinoma cells. Zhonghua Kou Qiang Yi Xue Za Zhi 2007;42:726-8
   PubMedGoogle Scholar
• Clarhaut J, Gemmill RM, Potiron VA, et al. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Coma S, Amin DN, Shimizu A, et al. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res 2010;70:3823-32
   PubMed Web of Science ®Google Scholar
• Miyato H, Tsuno NH, Kitayama J. Semaphorin 3C is involved in the progression of gastric cancer. Cancer Sci 2012;103:1961-6
   PubMed Web of Science ®Google Scholar
• Galani E, Sgouros J, Petropoulou C, et al. Correlation of MDR-1, nm23-H1 and H SEMA E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res 2002;22:2275-80
   PubMed Web of Science ®Google Scholar
• Tan AC, Jimeno A, Lin SH, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 2009;3:425-38
   PubMed Web of Science ®Google Scholar
• Lepore JJ, Mericko PA, Cheng L, et al. GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis. J Clin Invest 2006;116:929-39
   PubMed Web of Science ®Google Scholar
• Christensen C, Ambartsumian N, Gilestro G, et al. Proteolytic processing converts the repelling signal SEMA3E into an inducer of invasive growth and lung metastasis. Cancer Res 2005;65:6167-77
   PubMed Web of Science ®Google Scholar
• Tseng CH, Murray KD, Jou MF, et al. Sema3E/Plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS One 2011;6:e19396
   PubMed Web of Science ®Google Scholar
• Sakurai A, Gavard J, Annas-Linhares Y, et al. Semaphorin 3E initiates anti-angiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol Cell Biol 2010;30:3086-98
   PubMed Web of Science ®Google Scholar
• Casazza A, Finisguerra V, Capparuccia L, et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 2010;12:2684-98
   Google Scholar
• Sabag AD, Bode J, Fink D, et al. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS One 2012;7:e42912
   PubMed Web of Science ®Google Scholar
• Zhou X, Ma L, Li J, et al. Effects of SEMA3G on migration and invasion of glioma cells. Oncol Rep 2012;28:269-75
   PubMed Web of Science ®Google Scholar
• Kutschera S, Weber H, Weick A, et al. Differential endothelial transcriptomics identifies semaphorin 3G as a vascular class 3 semaphorin. Arterioscler Thromb Vasc Biol 2011;31:151-9
   PubMed Web of Science ®Google Scholar
• Kessler O, Shraga-Heled N, Lange T, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 2004;64:1008-15
   PubMed Web of Science ®Google Scholar
• Neufeld G, Sabag AD, Rabinovicz N, et al. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med 2012;2:a006718
   PubMed Web of Science ®Google Scholar
• Narazaki M, Tosato G. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood 2006;107:3892-901
   PubMed Web of Science ®Google Scholar
• Maione F, Molla F, Meda C, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse model. J Clin Invest 2009;119:3356-72
   PubMed Web of Science ®Google Scholar
• Casazza A, Fu X, Johansson I, et al. Systemic and targeted delivery of Semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol 2011;31:741-9
   PubMed Web of Science ®Google Scholar
• Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates Collapsin-1/Semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999;146:233-42
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Maione F, Capano S, Regano D, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012;122:1832-48
   PubMed Web of Science ®Google Scholar
• Potiron VA, Sharma G, Nasarre P, et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 2007;67:8708-15
   PubMed Web of Science ®Google Scholar
• Wong HK, Shimizu A, Kirkpatrick ND, et al. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 2012;14:84-94
   PubMed Web of Science ®Google Scholar
• Casazza A, Kigel B, Maione F, et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant semaphorin 3E isoform. EMBO Mol Med 2012;4:234-50
   PubMed Web of Science ®Google Scholar
• Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell 2012;22:145-52
   PubMed Web of Science ®Google Scholar
• Caunt M, Mak J, Liang WC, et al. Blocking Neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008;13:331-42
   PubMed Web of Science ®Google Scholar
• Serini G, Valdembri D, Zanivan S, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003;424:391-7
   PubMed Web of Science ®Google Scholar
• Casazza A, Laoui D, Wenes M, et al. Impeding macrophage entry into hypoxic tumor areas by SEMA3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity Cancer Cell. 2013;24:695-709
   Google Scholar
• Raskopf E, Vogt A, Standop J, et al. Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma. Z Gastroenterol 2010;48:21-7
   PubMed Web of Science ®Google Scholar
• Gray MJ, Van Buren G, Dallas NA, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 2008;100:109-20
   PubMedGoogle Scholar
• Dallas NA, Gray MJ, Xia L, et al. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res 2008;14:8052-60
   PubMed Web of Science ®Google Scholar
• Liang WC, Dennis MS, Stawicki S, et al. Function blocking antibodies to Neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2007;366:815-29
   PubMed Web of Science ®Google Scholar
• A study of MNRP1685A in patients with locally advanced or metastatic solid tumors. Available from: https://trialbulletin.com/lib/entry/ct-00747734; Clinical Trials.gov Identifier: NCT 00747734
   Google Scholar
• Schuch G, Machluf M, Bartsch G, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002;100:4622-8
   PubMed Web of Science ®Google Scholar
• Geretti E, van Meeteren LA, Shimizu A, et al. A mutated soluble neuropilin-2 B domain antagonizes VEGF bioactivity and inhibits tumor progression. Mol Cancer Res 2010;8:1063-73
   PubMed Web of Science ®Google Scholar
• Shin TH, Sung ES, Kim YJ, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 2014;13:651-61
   PubMed Web of Science ®Google Scholar
• Ueyama H, Horibe T, Nakajima O, et al. Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer. Biochem Biophys Res Commun 2011;414:60-6
   PubMed Web of Science ®Google Scholar
• Carrer A, Moimas S, Zacchigna S, et al. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res 2012;72:6371-81
   PubMed Web of Science ®Google Scholar
• Staton CA, Shaw LA, Valluru M, et al. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology 2011;59:274-82
   PubMed Web of Science ®Google Scholar
• Ito M, Ito G, Kondo M, et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21. 3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005;225(1):131-9
   PubMed Web of Science ®Google Scholar
• Tischoff I, Markwarth A, Witzigmann H, et al. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int J Cancer 2005;115:684-9
   PubMed Web of Science ®Google Scholar
• Roodink I, Kats G, van Kempen L, et al. Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. Am J Pathol 2008;173:1873-81
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Constantin B, Drabkin H, et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336-47
   PubMed Web of Science ®Google Scholar
• Drenberg CD, Livingston S, Chen R, et al. Expression of semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes, and secondary Mullerian tissues. Obstet Gynecol Int 2009:730739
   PubMedGoogle Scholar
• Kaneko S, Iwanami A, Nakamura M, et al. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat Med 2006;12:1380-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Kaneko S, Kikuchi K, et al. Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition. Mol Brain 2014;7:14
   PubMed Web of Science ®Google Scholar